Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. - Wikidata - wikimedia - TriplyDB

Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.

Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.

http://www.wikidata.org/entity/Q34529081

about

Curious cases: Acromegaly and schizophrenia: an incidental association?Drug-induced gynecomastia: an evidence-based review Antipsychotic-induced hyperprolactinemia Use of data mining at the Food and Drug Administration.The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.Pharmacovigilance for psychiatrists: An introduction Identifying unpredicted drug benefit through query of patient experiential knowledge: a proof of concept web-based system Hyperprolactinemia with antipsychotic drugs in children and adolescents.Cancer and schizophrenia: is there a paradox?Idiopathic granulomatous mastitis associated with risperidone-induced hyperprolactinemia The evolution of hyperprolactinaemia as an entity in psychiatric patients.Pituitary volume in psychosis: the first review of the evidence.Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.Pituitary hyperplasia: case series and literature review of an under-recognised and heterogeneous condition.Pharmacovigilance in children: detecting adverse drug reactions in routine electronic healthcare records. A systematic review.A risperidone-induced prolactinoma resolved when a woman with schizoaffective disorder switched to ziprasidone: a case report Computational models of neuronal biophysics and the characterization of potential neuropharmacological targets.Regarding "A Risperidone-induced Prolactinoma Resolved When A Woman with Schizoaffective Disorder Switched to Ziprasidone: A Case Report".Management of psychosis associated with a prolactinoma: case report and review of the literature Risperidone-induced acromegaly: a case report Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists.A well-being programme in severe mental illness. Baseline findings in a UK cohort.Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management.Management of schizophrenia in children and adolescents: focus on pharmacotherapy.Antipsychotic-induced hyperprolactinaemia.Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis.Pharmacogenetics of clinical response to risperidone.Use of asenapine in clinical practice for the management of bipolar mania.Association between Hyperprolactinemia and Granulomatous Mastitis.The Risk of Glioblastoma with TNF Inhibitors.Synthesis, Spectroscopic Characterization and DFT/TD-DFT Calculations of new Fluorescent Derivatives of Imidazo[4',5':3,4]Benzo[c]Isoxazole.Hyperprolactinaemia and acute psychosis: prolactinoma or medication-induced phenomenon?Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia.One-third of adult smokers have a mental illness.Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics.Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone.Frequency of hyperprolactinemia and its associations with demographic and clinical characteristics and antipsychotic medications in psychiatric inpatients in China.

P2860

Q27025160-0A1A649F-3D19-461D-A177-6D1F4D625D80 Q28272451-B84BC0CA-8D97-4EAE-9FE9-303665148653 Q28305237-10886C10-E50E-42FE-A625-674D3D91810C Q30982556-941BA4DB-B37A-4464-89E8-AD8294CD258C Q33619940-6C4A472E-7D7A-42EF-8AE8-CE4DF7B0704D Q33692129-740F3969-0896-456F-A618-71C8A643D1E3 Q34023668-C599D326-EB0E-4111-A03D-B66CFF3FF9AC Q34143459-288CC598-2563-4CBF-AB8D-3EEE447A7972 Q34183508-AA199881-22D2-4C90-BEC8-AD9EE2FF52CF Q34244926-644781CB-B2B0-49F5-B0E6-184AC109479B Q34591930-9E3798D6-4CC8-4CC3-AE92-6CDE4BE2839E Q34809978-D2E38BA6-EFB5-49EA-BA75-133D13226662 Q34925151-A8B64D3B-6C0F-4480-978D-183859214F94 Q34966395-A10E08CB-3D69-4D9A-868C-3D816D629313 Q35754726-B5FF8419-BB89-45AB-B6BF-56928C8405F8 Q35786391-C3112229-E6FC-4B57-A7A9-13F2AE96E928 Q36125536-104302C6-3C6A-4CFE-9A29-055507D48AA3 Q36322256-31C749F2-464C-437E-B26F-EA6D5FF09A93 Q36576250-769BA5D2-7498-4F83-9ED4-B8A5A2541D0F Q36737420-555853BE-7C9A-4FBB-B40F-A857BA04A055 Q36888242-A3244C66-43C0-4BEF-8DA0-DE45D4401256 Q37079013-5DF27798-1B46-436E-A2D2-1387D2C0F81A Q37112276-E6639999-6861-49BA-9E39-B8580B1BB045 Q37162791-47469CF9-2211-45A9-A811-7744AD6EF8C4 Q37427322-C2F59C8D-F812-427E-9033-D220D3E4B8C4 Q37747570-263AAFB5-1CAB-4452-99D3-736552625DA8 Q37833061-39C98F16-AD5B-43CD-9867-39AB720221BC Q37895702-639C8A1E-E53E-4081-A57A-2A714F872CBD Q37999566-7D9DDD2B-5554-417E-8317-CA221CAA9C29 Q38074712-02282108-0F0F-4DF8-997A-F99349ED6973 Q38093728-D5415898-EA91-428C-87E1-6B379BC71800 Q38679922-19FED2DB-F568-4315-A43C-4D5DA28B6B9F Q39956333-75A678E7-07CE-4724-8696-EEB00A6D6EB2 Q40228838-1FE1EA95-71E3-46AC-850F-68BD35A4EE09 Q43072098-93C71056-78C7-4AB0-A9BF-2CEF028F4EB1 Q46110645-1B580C55-13B3-45FE-8CD6-B3FBB325471E Q46156987-646845F5-9A2B-4843-B996-A23DF7CE5BC4 Q46597827-8911B7CA-5055-4E50-BA66-8EB797734B96 Q47350555-F98E0CF3-4BA9-4582-A472-740F7AB82F5A Q48397820-963BEEEA-7D86-4AD1-A682-E6DF86315FC1

P2860

Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.

http://www.wikidata.org/entity/Q34529081

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.

@ast

Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.

@en

Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.

@nl

type

label

Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.

@ast

Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.

@en

Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.

@nl

prefLabel

Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.

@ast

Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.

@en

Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.

@nl

P1433

Q34529081-65CFFA1B-A235-434B-99DB-ECC36C863D39

P1476

Q34529081-E977E958-C936-46D3-8629-466395298767

P2093

Q34529081-04BC00DB-C3EC-41E8-A777-B1679C0B0C84

Q34529081-6DDE5FC3-206D-49E5-99DB-12509A459C0A

Q34529081-8053F321-2971-4E6E-8CE3-3FD6FAF6068D

Q34529081-A7ABA974-DC23-4B6E-8FC7-1F8472A09311

P2860

Q34529081-33A45CF4-2031-4434-8771-1826BAEA82D0

Q34529081-3DF08AC6-A188-43DE-A37C-1E767D1E302A

Q34529081-3E556EE0-94E0-4EF1-BB46-B7676131D9BF

Q34529081-4DD05A54-DD2C-4F35-A49E-C809C0FFE30F

Q34529081-518AD136-C728-4821-BECF-19C8F91755AD

Q34529081-6EDEFDD7-4AC8-46F6-80BF-D32436FB1737

Q34529081-77F1BD24-1A7C-4C40-90B2-003A04566FD2

Q34529081-7C6B8FA5-6721-483E-8370-818C3257055B

Q34529081-8DD95198-A5FA-4EA5-AB18-E74F81D33DD0

Q34529081-97C6DC4F-8BC6-4488-B981-71935BDFB245

P304

Q34529081-BD4EEFB4-F203-49B4-83E9-061B58EBDB36

P31

Q34529081-084968CA-0629-4ED6-A8E1-5E28E419E742

P356

Q34529081-D52D58ED-D260-4CA5-8089-970142661983

P407

Q34529081-D82B3896-98F9-4435-A0A9-50604DBA350F

P433

Q34529081-88AE220C-94EB-4E86-A09A-3C1A2D9F5969

P478

Q34529081-E243109A-FA01-42C2-A368-5EC58E7F3419

P577

Q34529081-254A2C04-AD19-4665-AD30-7F257EE4748B

P5875

Q34529081-BA4E8354-E71F-4DE3-9EFD-ADDB1F359833

P698

Q34529081-B80C46A6-468D-4AA8-8EC5-6B6872D11AD4

P356

P1433

Pharmacotherapy

P1476

Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.

@en

P2093

Ana Szarfman

http://www.w3.org/2001/XMLSchema#string

Jonathan G Levine

http://www.w3.org/2001/XMLSchema#string

Joseph M Tonning

http://www.w3.org/2001/XMLSchema#string

P Murali Doraiswamy

http://www.w3.org/2001/XMLSchema#string

P2860

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

Anterior pituitary hypoplasia and dwarfism in mice lacking the dopamine transporter

Antiproliferative role of dopamine: loss of D2 receptors causes hormonal dysfunction and pituitary hyperplasia

Diagnostic and therapeutic approach to pituitary incidentalomas.

Perspectives on the use of data mining in pharmaco-vigilance.

Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database.

Physical health monitoring of patients with schizophrenia.

Control of lactotrop proliferation by dopamine: essential role of signaling through D2 receptors and ERKs.

Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.

Hyperprolactinemia: pathophysiology and management.

P304

748-758

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1592/PHCO.26.6.748

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2006-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7065896

http://www.w3.org/2001/XMLSchema#string

P698

16716128

http://www.w3.org/2001/XMLSchema#string